Fmoc-leucine (Synonyms: N-FMOC-leucine; NPC 15199; NSC 334290)

Name: Fmoc-leucine
Brand: MedChemExpress
SKU: HY-101064
Rating: 4.5 (1 reviews)

Cat. No.: HY-101064 Purity: 99.9% ee.: 100%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Fmoc-Leucine (N-FMOC-leucine) is an anti-inflammatory agent that not only promotes extracellular Ca²⁺ influx but also facilitates intracellular Ca²⁺ release. Fmoc-Leucine is a selective ligand for PPARγ (K_i = 15 μM), exhibiting insulin-sensitizing effects but with weak fatogenic activity. Fmoc-Leucine exhibits unique self-assembly properties and can form transient gels, stable gels, or crystals/2D sheets through different pathways. Fmoc-Leucine can be used in the research of diabetes, colitis, and bladder cancer.

For research use only. We do not sell to patients.

Fmoc-leucine Chemical Structure

CAS No. : 35661-60-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	In-stock	Estimated Time of Arrival: December 31
100 g	In-stock	Estimated Time of Arrival: December 31
500 g	In-stock	Estimated Time of Arrival: December 31
> 100 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Fmoc-leucine:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

View All Calcium Channel Isoform Specific Products:

View All Isoforms

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

PPARγ

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	23.3 μM Compound: 13	Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake at 30 to 300 uM incubated for 15 mins by liquid scintillation counting method Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake at 30 to 300 uM incubated for 15 mins by liquid scintillation counting method	[PMID: 32608236]

In Vitro

Fmoc-Leucine (1 mM, 24 h) significantly enhances the interaction between PPARγ and SRC-1 in RK13 cells^[1].
Fmoc-Leucine (10 μM, 0-6 d) induces the expression of LPL and aP2 in 3T3-L1 cells, but its ability to accumulate lipids is significantly lower than that of Rosiglitazone (HY-17386)^[1].
Fmoc-Leucine (0.1-2 mM) rapidly and continuously increases [Ca²⁺]i in MDCK and BFTC cells in a concentration-dependent manner with an EC₅₀ in MDCK cells of 0.5 mM^[3][4].
Fmoc-Leucine induces the release of Ca²⁺ from the endoplasmic reticulum and activated the influx of Ca²⁺ in BFTC bladder cancer cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	3T3-L1 cells
Concentration:	10 μM
Incubation Time:	0, 2, 3, 4, 6 d
Result:	Induced the expression of LPL and aP2.

In Vivo

Fmoc-Leucine (10-60 mg/kg, i.p., once daily for 7 or 14 days) improves mice glucose tolerance in both normal and diet-induced insulin resistance and diabetes models, and has a synergistic effect with Rosiglitazone^[1].
Fmoc-Leucine (50 mg/kg, i.p., once daily for 4 days) reduces the severity of TNBS-induced colitis in the mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal mice, diet-induced insulin resistance model and diabetic db/db mice model established in C57BL/6J mice^[1]
Dosage:	10, 30 and 60 mg/kg
Administration:	Intraperitoneal injection (i.p.), once daily for 7 or 14 days
Result:	Significantly improved glucose clearance rate, and reduce the plasma glucose and insulin levels 1 hour after the meal. Induced the expression of aP2 and LPL mRNA in adipose tissue. Did not cause weight gain.

Animal Model:	TNBS-induced colitis model established in C57BL/6J mice^[1]
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection (i.p.), once daily for 4 days
Result:	Reduced the severity of colitis.

Molecular Weight

353.42

Formula

C₂₁H₂₃NO₄

CAS No.

35661-60-0

Appearance

Solid

Color

White to off-white

SMILES

CC(C)C[C@@H](C(O)=O)NC(OCC1C2=C(C3=C1C=CC=C3)C=CC=C2)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (141.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8295 mL	14.1475 mL	28.2949 mL
5 mM	0.5659 mL	2.8295 mL	5.6590 mL
10 mM	0.2829 mL	1.4147 mL	2.8295 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (252 KB) HNMR (117 KB) RP-HPLC (198 KB)

Handling Instructions (2659 KB)

References

[1]. Rocchi S, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell. 2001 Oct;8(4):737-47. [Content Brief]

[2]. Paul S, et al. Complex Pathways Drive Pluripotent Fmoc-Leucine Self-Assemblies. Angew Chem Int Ed Engl. 2024 Sep 9;63(37):e202406220. [Content Brief]

[3]. Jan CR, Yu CC, Huang JK. NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33. [Content Brief]

[4]. Jan CR, et al. Effect of NPC-15199 on Ca2+ levels in renal tubular cells. Chin J Physiol. 2002 Sep 30;45(3):117-22. Erratum in: Chin J Physiol. 2003 Dec 31;45(4):200. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8295 mL	14.1475 mL	28.2949 mL	70.7374 mL
	5 mM	0.5659 mL	2.8295 mL	5.6590 mL	14.1475 mL
	10 mM	0.2829 mL	1.4147 mL	2.8295 mL	7.0737 mL
	15 mM	0.1886 mL	0.9432 mL	1.8863 mL	4.7158 mL
	20 mM	0.1415 mL	0.7074 mL	1.4147 mL	3.5369 mL
	25 mM	0.1132 mL	0.5659 mL	1.1318 mL	2.8295 mL
	30 mM	0.0943 mL	0.4716 mL	0.9432 mL	2.3579 mL
	40 mM	0.0707 mL	0.3537 mL	0.7074 mL	1.7684 mL
	50 mM	0.0566 mL	0.2829 mL	0.5659 mL	1.4147 mL
	60 mM	0.0472 mL	0.2358 mL	0.4716 mL	1.1790 mL
	80 mM	0.0354 mL	0.1768 mL	0.3537 mL	0.8842 mL
	100 mM	0.0283 mL	0.1415 mL	0.2829 mL	0.7074 mL

Fmoc-leucine Related Classifications

Metabolic Disease Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Fmoc-leucine (Synonyms: N-FMOC-leucine; NPC 15199; NSC 334290)

Customer Review

Other Forms of Fmoc-leucine:

Fmoc-leucine Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Calcium Channel Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Fmoc-leucine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fmoc-leucine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report